deltatrials
Completed PHASE2 NCT00101101

Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma

A Phase II Trial Using a Universal GM-CSF-Producing and CD40L-Expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-Based Vaccines for Patients With Mantle Cell Lymphoma

Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Conditions Lymphoma
Interventions Autologous Tumor Cell-Based Vaccine Cyclophosphamide Dexamethasone Doxorubicin IL-2 Prednisone Vincristine
Updated 17 times since 2017 Last updated: Aug 4, 2023 Started: Jul 31, 2004 Primary completion: Oct 31, 2012 Completion: Jun 14, 2021

A PHASE2 clinical study on Lymphoma, this trial is completed. The trial is conducted by H. Lee Moffitt Cancer Center and Research Institute and has accumulated 17 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

17 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Sep 2023 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Sep 2022 — Sep 2023 [monthly]

    Active Not Recruiting PHASE2

  5. Dec 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

▶ Show 12 earlier versions

  1. Oct 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE2

  2. Jan 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Mar 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE2

  5. Feb 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE2

  6. Oct 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE2

  7. May 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE2

  8. Dec 2018 — May 2019 [monthly]

    Active Not Recruiting PHASE2

  9. Aug 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE2

  10. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE2

  11. Feb 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  12. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Jul 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • H. Lee Moffitt Cancer Center and Research Institute
  • Lymphoma Research Foundation
  • National Cancer Institute (NCI)
  • Novartis
Data source: H. Lee Moffitt Cancer Center and Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Tampa, United States